Literature DB >> 7510621

Torsade de pointes. Mechanisms and management.

C Napolitano1, S G Priori, P J Schwartz.   

Abstract

Torsade de pointes is a polymorphic ventricular tachycardia showing a peculiar electrocardiographic pattern characterised by a continuous twisting in QRS axis around an imaginary baseline. An abnormally prolonged QT interval is actually associated with torsade de pointes and it is constantly observed in the sinus beats preceding the onset of the arrhythmic event. Prolongation of ventricular repolarisation associated with the development of torsade de pointes can be observed in many clinical conditions, commonly referred to as prolonged QT syndromes, which can be divided into two major groups: (a) idiopathic long QT syndrome (LQTS), which include the Jervell-Lange-Nielsen and the Romano-Ward syndromes; and (b) acquired prolonged QT syndromes, which are largely iatrogenic and may follow treatment with antiarrhythmic drugs, tricyclic antidepressants, phenothiazines or macrolide antibiotics, and may be associated with metabolic disturbances (hypokalaemia, hypocalcaemia and hypomagnesaemia). Clinical studies have provided criteria for the definition and guidelines for the management of torsade de pointes, while the electrophysiological mechanisms responsible for its onset are still unclear. Two pathogenetic hypotheses have been proposed to account for the electrophysiological mechanisms underlying the condition: (a) re-entry due to a dispersion of refractory periods; and (b) triggered activity initiated by either early or delayed after-depolarisations. Both mechanisms are supported by clinical and experimental observations but a conclusive answer is not yet available.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510621     DOI: 10.2165/00003495-199447010-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  61 in total

Review 1.  Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations?

Authors:  B Surawicz
Journal:  J Am Coll Cardiol       Date:  1989-07       Impact factor: 24.094

2.  Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism.

Authors:  S Nattel; S Ranger; M Talajic; R Lemery; D Roy
Journal:  Am J Med       Date:  1990-08       Impact factor: 4.965

3.  In vitro validation of a new cardiac catheter technique for recording monophasic action potentials.

Authors:  M R Franz; D Burkhoff; H Spurgeon; M L Weisfeldt; E G Lakatta
Journal:  Eur Heart J       Date:  1986-01       Impact factor: 29.983

4.  Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs.

Authors:  N O Fowler; D McCall; T C Chou; J C Holmes; I B Hanenson
Journal:  Am J Cardiol       Date:  1976-02       Impact factor: 2.778

5.  QT prolongation and recurrent "torsades de pointes" during erythromycin lactobionate infusion.

Authors:  D Guelon; B Bedock; C Chartier; J P Haberer
Journal:  Am J Cardiol       Date:  1986-09-15       Impact factor: 2.778

6.  Disopyramide-induced QT prolongation and ventricular tachyarrhythmias.

Authors:  N Riccioni; M Castiglioni; C Bartolomei
Journal:  Am Heart J       Date:  1983-05       Impact factor: 4.749

7.  Sudden, unexpected death in avid dieters using the liquid-protein-modified-fast diet. Observations in 17 patients and the role of the prolonged QT interval.

Authors:  J M Isner; H E Sours; A L Paris; V J Ferrans; W C Roberts
Journal:  Circulation       Date:  1979-12       Impact factor: 29.690

8.  Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone.

Authors:  J W Mason; L M Hondeghem; B G Katzung
Journal:  Circ Res       Date:  1984-09       Impact factor: 17.367

9.  Disopyramide-induced Torsade de Pointes.

Authors:  D Tzivoni; A Keren; S Stern; S Gottlieb
Journal:  Arch Intern Med       Date:  1981-06

10.  Open clinical studies at a referral center: chronic maintenance tocainide therapy in patients with recurrent sustained ventricular tachycardia refractory to conventional antiarrhythmic agents.

Authors:  J D Maloney; R G Nissen; J M McColgan
Journal:  Am Heart J       Date:  1980-12       Impact factor: 4.749

View more
  22 in total

Review 1.  Effects of H1 antihistamines on animal models of QTc prolongation.

Authors:  J Gras; J Llenas
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

Review 2.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

Review 3.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.

Authors:  M D Drici; N Clément
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine.

Authors:  Sabrina Obers; Ingo Staudacher; Eckhard Ficker; Adrienne Dennis; Ronald Koschny; Hande Erdal; Ramona Bloehs; Jana Kisselbach; Christoph A Karle; Patrick A Schweizer; Hugo A Katus; Dierk Thomas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-13       Impact factor: 3.000

6.  Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.

Authors:  Dierk Thomas; Bettina C Hammerling; Kezhong Wu; Anna-Britt Wimmer; Eckhard K Ficker; Glenn E Kirsch; Mary C Kochan; Barbara A Wible; Eberhard P Scholz; Edgar Zitron; Sven Kathöfer; Volker A W Kreye; Hugo A Katus; Wolfgang Schoels; Christoph A Karle; Johann Kiehn
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

7.  The antipsychotic drug chlorpromazine inhibits HERG potassium channels.

Authors:  Dierk Thomas; Kezhong Wu; Sven Kathöfer; Hugo A Katus; Wolfgang Schoels; Johann Kiehn; Christoph A Karle
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

Review 8.  QT prolongation with antimicrobial agents: understanding the significance.

Authors:  Robert C Owens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.

Authors:  Dierk Thomas; Anna-Britt Wimmer; Kezhong Wu; Bettina C Hammerling; Eckhard K Ficker; Yuri A Kuryshev; Johann Kiehn; Hugo A Katus; Wolfgang Schoels; Christoph A Karle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-20       Impact factor: 3.000

Review 10.  Drug-induced torsade de pointes. Incidence, management and prevention.

Authors:  T S Faber; M Zehender; H Just
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.